MKI67 and neoplasm: For patients with pancreatic NET and high tumor burden, Ki67 ≥ 10% or progressive disease, a chemotherapy based on a regimen using streptozotocin and temozolomide in combination with 5-fluorouracil or capecitabine are available (Rinke et al. 2021).